Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 6Neoplasms 4Colorectal Neoplasms 4Stomach Neoplasms 3Glioma 2Weight Loss 1Triple Negative Breast Neoplasms 1Solid Tumor Cancer 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Refractory Solid Tumors 1Recurrence 1Rectal Neoplasms 1Pseudomyxoma Peritonei 1Peritoneal Neoplasms 1Pancreatic cancer, adult 1Pancreatic Diseases 1Ovarian Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neuroblastoma 1Neoplasms, Cystic, Mucinous, and Serous 1Neoplasm Metastasis 1Metastatic Pancreatic Adenocarcinoma 1Mesothelioma 1Malignant Solid Neoplasm 1Head and Neck Neoplasms 1Gliosarcoma 1

Interventions

irinotecan sucrosofate 1Oxaliplatin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Small Intestine Cancer × irinotecan sucrosofate × Clear all
NCT07060014 2025-07-11

NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers

The Methodist Hospital Research Institute

Phase 1 Not yet recruiting
22 enrolled
Gastrointestinal

Advanced Small Intestine Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡